Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fruquintinib × Tegafur × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 10 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Hepatocellular 4 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 HER2-positive Gastric Cancer 2 Colonic Neoplasms 2 Breast Neoplasms 2 Stage IA Pancreatic Adenocarcinoma 1 Mouth Neoplasms 1 Malignant Neoplasms of Digestive Organs 1 Immunotherapy 1 Head and Neck Neoplasms 1 Fruquintinib 1 Extrapancreatic Neuroendocrine Tumor 1 Esophageal Neoplasms 1 Efficacy and Safety 1 Drug-Related Side Effects and Adverse Reactions 1 Biliary Tract Neoplasms 1 Advanced Pancreatic Cancer 1 Advanced Biliary Tract Carcinoma 1 Adenoma, Islet Cell 1 Adenocarcinoma 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡